首页> 外文OA文献 >Chromosomal Localization of DNA Amplifications in Neuroblastoma Tumors Using cDNA Microarray Comparative Genomic Hybridization1
【2h】

Chromosomal Localization of DNA Amplifications in Neuroblastoma Tumors Using cDNA Microarray Comparative Genomic Hybridization1

机译:使用cDNA微阵列比较基因组杂交技术在神经母细胞瘤肿瘤中DNA扩增的染色体定位

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Conventional comparative genomic hybridization (CGH) profiling of neuroblastomas has identified many genomic aberrations, although the limited resolution has precluded a precise localization of sequences of interest within amplicons. To map high copy number genomic gains in clinically matched stage IV neuroblastomas, CGH analysis using a 19,200-feature cDNA microarray was used. A dedicated (freely available) algorithm was developed for rapid in silico determination of chromosomal localizations of microarray cDNA targets, and for generation of an ideogram-type profile of copy number changes. Using these methodologies, novel gene amplifications undetectable by chromosome CGH were identified, and larger MYCN amplicon sizes (in one tumor up to 6 Mb) than those previously reported in neuroblastoma were identified. The genes HPCAL1, LPIN1/KIAA0188, NAG, and NSE1/LOC151354 were found to be coamplified with MYCN. To determine whether stage IV primary tumors could be further subclassified based on their genomic copy number profiles, hierarchical clustering was performed. Cluster analysis of microarray CGH data identified three groups: 1) no amplifications evident, 2) a small MYCN amplicon as the only detectable imbalance, and 3) a large MYCN amplicon with additional gene amplifications. Application of CGH to cDNA microarray targets will help to determine both the variation of amplicon size and help better define amplification-dependent and independent pathways of progression in neuroblastoma.
机译:神经母细胞瘤的常规比较基因组杂交(CGH)分析已鉴定出许多基因组畸变,尽管有限的分辨率使得目的序列在扩增子中无法精确定位。为了绘制临床匹配的IV期神经母细胞瘤中高拷贝数的基因组增益,使用了使用19,200个特征cDNA微阵列的CGH分析。开发了一种专用(免费)算法,用于计算机快速测定微阵列cDNA靶标的染色体定位,并生成拷贝数变化的表意文字类型的资料。使用这些方法,鉴定了染色体CGH无法检测到的新基因扩增,并且鉴定了比以前在神经母细胞瘤中报道的MYCN扩增子更大的大小(在一个肿瘤中高达6 Mb)。发现HPCAL1,LPIN1 / KIAA0188,NAG和NSE1 / LOC151354基因与MYCN共扩增。为了确定IV期原发肿瘤是否可以根据其基因组拷贝数谱进一步细分,进行了分级聚类。微阵列CGH数据的聚类分析确定了三组:1)没有明显的扩增,2)一个小的MYCN扩增子是唯一可检测到的失衡,以及3)一个带有额外基因扩增的大的MYCN扩增子。 CGH在cDNA微阵列靶标上的应用将有助于确定扩增子大小的变化,并有助于更好地定义神经母细胞瘤中依赖扩增和独立的进展途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号